Info@ThinkPinkRocks.org

CardioDx, Inc., a molecular diagnostics company specializing in cardiovascular genomics, today announced a national specimen-draw agreement with Quest Diagnostics DGX, +1.23{20b543310651bf6f3679f07daa0e532ca50e05ab066d8bcfc12d35f979f65272} the world’s leading provider of diagnostic information services, that will expand patient and clinician access to the Corus CAD lab-developed blood test for aiding the assessment of obstructive coronary artery disease (CAD).

More:
CardioDx announces national agreement with Quest Diagnostics to expand access to Corus CAD blood test

Scroll to Top